Virginia Eye Consultants   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Norfolk VA United States

Organization Overview

First Clinical Trial
2011
NCT01505088
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Virginia Ehe Consultants

Active Ingredients

Drugs in Phase 4 Trials (2)

ganciclovir (cytovene) (1 trial)

hydroxypropyl cellulose (Lacrisert) (1 trial)

Drugs in Phase 3 Trials (4)

loteprednol (lotemax) (2 trials)

prednisone (meticorten) (1 trial)

sodium citrate (1 trial)

urea (2 trials)

Drugs in Phase 2 Trials (1)

ru-101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoviridae Infections (Phase 4)

Blepharitis (Phase 2)

Conjunctivitis (Phase 4)

Dry Eye Syndromes (Phase 2)

Eye Infections (Phase 3)

Inflammation (Phase 3)

Iridocyclitis (Phase 3)

Keratoconjunctivitis (Phase 4)

Keratoconjunctivitis Sicca (Phase 2)

Uveitis (Phase 3)

Uveitis, Anterior (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 7